Welcome to the Oncomine Blog

What is Biomarker Testing and Why is it Important in Oncology?

Thermo Fisher Scientific is committed to bringing advanced molecular testing to clinicians and their patients across indications including oncology, infectious disease, and reproductive health so that all can realize the promise of Precision Medicine.

Fundamental to this effort, we have developed fast and easy-to-use Next-Generation Sequencing (NGS) assays and platforms to bring this critically important technology closer to the patient. However, a recent study estimates that approximately 30% of cancer patients are not tested using NGS for genomic profiling [Hess LM, et al, J Molecular Diagnostics May 2022]. This highlights the stark reality that access to advanced testing and genomics-informed treatment remains a great challenge that must be addressed.

One of the universal challenges to advancing NGS-based precision medicine is a lack of awareness and appreciation for the clinical benefit of molecular diagnostics. Education of both patients and clinicians is critical to increasing access to the growing list of efficacious targeted therapies.

To address this education deficit, we are honored to support the BEAT Cancer Coalition, which has initiated a series of educational videos intended to describe the importance of biomarker testing for more effective treatment planning and improved outcomes.

In the first of these videos, leading pathologists define biomarker testing and describe the value it can bring to people living with cancer. Use the links below to access these videos in either English or French.

beat-cancer-blog-videos copy

 

Learn more about BEAT Cancer Coalition.

 

Share this article
Thermo Fisher Scientific Staff
Article by:

Thermo Fisher Scientific Staff


Genomic Profiling from Initial Assessment to Detection of Measurable Residual Disease (MRD): How NGS Can Rapidly Deliver Key Insights for Myeloid Neoplasms

In his recent webinar, Dr. Bevan Tandon makes a compelling case for how next-generation sequencing (NGS) can deliver rapid insights for myeloid neoplasm from initial assessment to detection of measurable residual disease (MRD).

Bevan Tandon, MD,...

Next-Generation Sequencing (NGS) for Clonality Testing

Lymphoproliferative disorders such as acute lymphoblastic leukemia (ALL), lymphomas, and multiple myeloma comprise the majority of new blood cancer cases diagnosed each year.

These diseases affect cells of the adaptive immune system, including...

Using Next-Generation Sequencing (NGS) to Derive Key Insights in MPN Testing

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of disorders that include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), often referred to as the “classic MPNs.” MPNs are characterized by uncontrolled...